EGFR and non-small cell lung carcinoma: The epidermal growth factor receptor (EGFR) mutations are the most common oncogenic driver mutations in pulmonary non‐small cell lung cancer (NSCLC), having been found to occur in 11%–16% of patients in Western countries and around 50% of Asian patients.1